+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets

International Journal of Molecular Sciences 20(3)

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary disease with a median survival of 2⁻4 years after diagnosis. A significant number of IPF patients have risk factors, such as a history of smoking or concomitant emphysema, both of which can predispose the patient to lung cancer (LC) (mostly non-small cell lung cancer (NSCLC)). In fact, IPF itself increases the risk of LC development by 7% to 20%. In this regard, there are multiple common genetic, molecular, and cellular processes that connect lung fibrosis with LC, such as myofibroblast/mesenchymal transition, myofibroblast activation and uncontrolled proliferation, endoplasmic reticulum stress, alterations of growth factors expression, oxidative stress, and large genetic and epigenetic variations that can predispose the patient to develop IPF and LC. The current approved IPF therapies, pirfenidone and nintedanib, are also active in LC. In fact, nintedanib is approved as a second line treatment in NSCLC, and pirfenidone has shown anti-neoplastic effects in preclinical studies. In this review, we focus on the current knowledge on the mechanisms implicated in the development of LC in patients with IPF as well as in current IPF and LC-IPF candidate therapies based on novel molecular advances.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 066446180

Download citation: RISBibTeXText

PMID: 30704051

DOI: 10.3390/ijms20030593

Related references

New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 380(9842): 680-688, 2012

Alteration of p53 gene in lung cancer and pulmonary fibrosis-related epithelial lesions in patients with idiopathic pulmonary fibrosis. Proceedings of the American Association for Cancer Research Annual Meeting (41): 295-296, 2000

Lung Cancer in Patients With Combined Pulmonary Fibrosis and Emphysema and Idiopathic Pulmonary Fibrosis. A Descriptive Study in a Spanish Series. Archivos de Bronconeumologia 53(6): 304-310, 2016

Molecular targets in drugs discovery in idiopathic pulmonary fibrosis. Work in progress. American Journal of Respiratory Cell and Molecular Biology 29(3 Suppl.): S98-101, 2003

Molecular targets for drug discovery in idiopathic pulmonary fibrosis: Work in progress. American Journal of Respiratory Cell and Molecular Biology 29(3 Part 2): S98-S101, 2003

Exploitation of Novel Molecular Targets to Treat Idiopathic Pulmonary Fibrosis: A Drug Discovery Perspective. Current Medicinal Chemistry 24(22): 2439-2458, 2017

Recent Advances in Molecular Targets and Treatment of Idiopathic Pulmonary Fibrosis: Focus on Tgf Signaling and the Myofibroblast. Current Medicinal Chemistry 16(11): 1400-1417, 2009

Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annual Review of Medicine 64: 265-276, 2013

Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis. Respirology Case Reports 6(8): E00363, 2018

Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. Respiratory Research 18(1): 120, 2018

Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast. Current Medicinal Chemistry 16(11): 1400-1417, 2009

Idiopathic pulmonary fibrosis: molecular mechanisms and possible therapeutic strategies. Archivum Immunologiae et Therapiae Experimentalis 48(6): 539-545, 2001

Molecular Mechanisms of and Possible Treatment Strategies for Idiopathic Pulmonary Fibrosis. Current Pharmaceutical Design 11(30): 3943-3971, 2005

Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Current Pharmaceutical Design 11(30): 3943-3971, 2005

Trade-offs in aging lung diseases: a review on shared but opposite genetic risk variants in idiopathic pulmonary fibrosis, lung cancer and chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 24(3): 309-317, 2018